IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.	: 10/518,870	Confirmation No.:	5652	
Applicant	(s): SHICHIRI, et al.	Group Art Unit: Examiner:	1614 TBA	
Filed:	August 29, 2005			
For:	NOVEL USE OF ANSAMYCIN NOVEL ANGIOGENESIS INHII		27123 METHOD OF SCREENING	
	SUPPLEMENTAL INFORMATIO	N DISCLOSURE ST	ATEMENT	
Commissi P.O. Box	Amendment oner for Patents 1450 a, VA 22313-1450			
Sir:				
made of re The Exam their teach 1.	This Information Disclosure Statem 97 and 1.98. The items listed on Form Pecord to assist the Patent and Trademark iner is respectfully requested to fully coring. For each of the following items listed on not in the English language, an English I thereof or a concise explanation of the respective statement o	TO-1449, a copy of wood of the company of the enclosed copy of language translation of	rhich is enclosed, are ion of this application. independently ascertain Form PTO-1449 that is f that item or a portion	
	For each of the following items listed on not in the English language, a concise ex incorporated in the specification of the a	planation of the releva	ance of that item is	
	Any copy of the items listed on the enclosed with this Information Disclosur submitted to the Patent and Trademark (re Statement was previ	iously cited by or	
	No fee is due under 37 C.F.R. §1.17(p) f since it is being filed in compliance with		sclosure Statement	

Docket No. <u>4439-4028</u> Serial No. <u>10/518,870</u>

		37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or
		37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
		37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
		37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5.	since in para Allow	e is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified agraph 4 above but before the mailing date of a final action or a Notice of ance (where there has been no prior final action), and is accompanied by one of trifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6.	it is be paragr	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(c), after the period specified in aph 4 above but before the mailing date of a final action or a notice of unce (where there has been no prior final action):
		A check in the amount of \$180.00 is enclosed in payment of the fee.
		Charge the fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7.	it is be action	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since sing filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final or a notice of allowance, whichever comes first, but before payment of the issued is accompanied by:
		ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and
		e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 elow.
8.	This In	nformation Disclosure Statement is being filed in compliance with:
	a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
	b. 🗌	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the

Docket No. <u>4439-4028</u> Serial No. <u>10/518,870</u>

	attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).
	c. The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.
9.	I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10.	This document is accompanied by ⊠ a Search Report for corresponding European application number EP 03 73 3506.
11.	A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).
	Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No
X	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. <u>13-4500</u> , Order No. <u>4439-4028</u>
Dated: So	Respectfully submitted, MORGAN & FINNEGAN, L.L.P. eptember 24, 2007 By:
	Sonja Reenan Registration No. <u>56,390</u>
	ndence Address: Associated With Customer Number:
, ,	5-8700 Telephone 5-8701 Facsimile

Attorney Docket:	Serial No.:
4439-4028	10/718,870
Applicant:	

INFORM		ORM PTO-1449A ON DISCLOSURE CIT. U.S. 1		Filing Augus	HIRI, et al.	CUMENT	1614	Art Unit:	
Examiner Initial		Patent/Publication Number 1		Publication/Issue Date			Na	Filing Date	

				,					
			FORFIC	N DATI	ENT DOCUME	'NTC			
Examiner Initial		Patent Number	Public	cation ate	Countr		Copy Filed	Transla	tion
/A.P./	1.	WO 99/58126	18.11.9		PCT		⊠ Yes	☐ Yes ☐ No ☐ A	Abstract N/A
							☐ Yes	☐ Yes ☐ No ☐ A	Abstract N/A
							☐ Yes	☐ Yes ☐ No ☐ A	Abstract N/A
							☐ Yes	Yes No A	Abstract N/A
							☐ Yes	Yes No	Abstract N/A
							☐ Yes	☐ Yes ☐ No ☐ A	Abstract N/A

Examiner	/Anna Pagonakis/	Date Considered	10/14/2008	
EXAMINER:	: Initial if reference considered, whether or not citation is in conformance with MPEP §609.			
	Draw line through citation if not in conformance and not considered.			
	Include copy of this form with next communication to Applican	nt.		

FORM PTO-1449B

INFORMATION DISCLOSURE CITATION

		1450 10
Attorney Docket:	Serial No.:	
4439-4028	10/518,870	
Applicant:		
SHICHIRI, et al.		
Filing Date:	Group Art Unit:	
August 29, 2005	1614	

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Cite No. 1 Examiner journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where Initials* published. Communication with Supplementary European Search Report for Application Number EP 03-73-3506. MALKOWSKA-ZWIERZ, "Anti-Angiogenic Effects of Some Anti-Microbial Drugs", /A.P./International Journal of Oncology, vol. 7: 968, XP008050065, 1995. GIDOH et al., "Determination Of Three Main Antileprosy Drugs And Their Main Metabolites In Serum By High-Performance Liquid Chromatography", Journal of /A.P./ Chromatography, 223:379-392, 1981. RATTI et al., "Quantitative Assay of Rifampicin And Its Main Metabolite 25-/A.P./ Desacetylrifampicin In Human Plasma By Reversed-Phase High Performance Liquid Chromatography", Journal of Chromatography, 225:526-531, 1981. ACOCELLA, "Clinical Pharmacokinetics of Rifampicin", Clinical Pharmacokinetics, 3:108-/A.P./ 5. 127, 1978.

Examiner Signature /Anna Pagonakis/ Date Considered	09/23/2008
---	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.